Artelo Biosciences Inc represents the values of innovation, advanced scientific research, and dedication to improving patient outcomes. The company's corporate philosophy centers around leveraging cutting-edge technologies and scientific expertise to develop novel therapeutics for various medical conditions. Artelo Biosciences Inc strives to prioritize patient needs and deliver impactful solutions through its pipeline of targeted therapies. With a commitment to rigorous clinical development and strategic partnerships, Artelo Biosciences Inc aims to revolutionize the healthcare industry by addressing unmet medical needs and enhancing the quality of life for patients worldwide.

Artelo Biosciences Inc primarily operates in the United States and United Kingdom.

Artelo Biosciences Inc has achieved several notable milestones. These include securing FDA Rare Pediatric Disease Designation for its lead candidate, ART27.13, which is being developed as a potential treatment for Sanfilippo Syndrome. The company has successfully completed a Phase 1 clinical trial for ART12.11, its cannabinoid receptor agonist, demonstrating positive safety and tolerability results. Artelo Biosciences has also established valuable collaborations and partnerships with esteemed institutions and organizations, such as the University of Colorado, for further advancement of its research and development programs. These milestones highlight the company's commitment to developing innovative therapies and advancing scientific understanding in the field of biosciences.

Artelo Biosciences Inc. is a biopharmaceutical company specializing in the development of innovative treatments for cancer and other diseases. Established in 2011, Artelo Biosciences is headquartered in San Diego, California. The company is dedicated to leveraging the potential of cannabinoid-based therapeutics, focusing on the modulation of the endocannabinoid system for various medical applications. With a strong research and development focus, Artelo is actively engaged in developing novel formulations and delivery methods to maximize the therapeutic potential of cannabinoids. Artelo Biosciences Inc. is committed to advancing the understanding and application of cannabinoids in the pursuit of improving the lives of patients globally.

The main competitors of Artelo Biosciences Inc in the market include pharmaceutical companies such as GW Pharmaceuticals, Zynerba Pharmaceuticals, and InMed Pharmaceuticals. These companies, like Artelo Biosciences, focus on developing innovative therapies for various medical conditions, including neurological and cancer-related disorders. Artelo Biosciences Inc competes with these industry players by leveraging its unique drug development platform and research capabilities to bring novel and effective treatments to the market.

Artelo Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Artelo Biosciences Inc is focused on developing and commercializing high-quality therapeutics targeting a variety of diseases and conditions. The company utilizes a combination of in-house research and strategic partnerships to drive its product development. Artelo Biosciences aims to identify novel mechanisms of action and develop innovative therapies that have the potential to make a significant impact on patient care. By leveraging its expertise in the biomedical field, the company aims to provide effective and safe treatment options for unmet medical needs. Artelo Biosciences Inc is committed to advancing healthcare through the development of cutting-edge pharmaceutical solutions.

Коефициентът на цена спрямо печалбата (КЦП) на Artelo Biosciences е -0,55.

Коефициентът на цена към оборот (KUV) на Artelo Biosciences е 0.

AlleAktien качественият резултат за Artelo Biosciences е 4/10.

Приходите не могат да бъдат изчислени в момента за Artelo Biosciences.

очаквана Artelo Biosciences печалба е -5,84 млн. USD.

Artelo Biosciences Inc is a UK-based biotechnology company focused on the development and commercialization of therapeutics for the treatment of central nervous system (CNS) diseases. The company's business model is based on developing innovative drug candidates and bringing them through clinical trials and regulatory approval processes to eventually bring them to the global market. The company specializes in two therapy areas: pain management and treatments for neurological diseases such as anxiety disorders or Alzheimer's. In addition to drug development, Artelo Biosciences is also working on developing diagnostic tools and biomarkers to monitor disease progression and treatment efficacy. The company utilizes its proprietary technology platform to develop cannabinoid-based therapeutics targeting the needs of the endocannabinoid system (ECS). The ECS is an important physiological regulator involved in pain, inflammation, anxiety, mood, and memory control. Artelo Biosciences has recognized the potential of cannabinoid-based therapeutics to modulate these important body regulations and aims to expand its innovative product pipeline in this field. One of the key products in the development phase is ART12.11, a novel cannabinoid-based medication for the treatment of physical pain and inflammation. Artelo Biosciences is also focused on the development of ANT-011, a non-psychoactive cannabinoid preparation for the treatment of anxiety and mood disorders. Both products are in Phase 2a clinical trials and could provide effective pain and anxiety therapy to patients in the near future. Artelo Biosciences is also working on leveraging the benefits of cannabinoid-based therapeutics in the animal world. The company has entered into a partnership with veterinary health firm VetRelief to develop cannabinoid-based therapeutics for the treatment of pain and inflammation in pets. To secure funding and drive growth, Artelo Biosciences recently successfully completed a capital raise. A total of $7 million was raised, primarily to fund clinical trials and further develop the product pipeline. Overall, the business model of Artelo Biosciences is based on the development and commercialization of cannabinoid-based therapeutics for the treatment of CNS diseases. The company utilizes its proprietary technology platform to develop novel and innovative drug candidates tailored to the needs of the endocannabinoid system. With a strong product pipeline and a growing financial base, Artelo Biosciences is well-positioned to develop the next wave of potential therapeutic solutions and revolutionize the global pharmaceutical market.

Artelo Biosciences разпределя дивидента от 0 USD на плащания годишно.

Дивидентата за Artelo Biosciences в момента не може да бъде изчислена или компанията не разпределя дивиденти.

ISIN на Artelo Biosciences е US04301G2012.

WKN на Artelo Biosciences е A2PNJU.

Тикерът на Artelo Biosciences е ARTL.

През последните 12 месеца Artelo Biosciences изплати дивиденда в размер на . Това съответства на дивидендна доходност от около . За следващите 12 месеца се очаква Artelo Biosciences да изплати дивиденда в размер на 0 USD.

Дивидентната доходност на Artelo Biosciences в момента е .

Artelo Biosciences изплаща дивидент на тримесечие. Той се разпределя в месеците .

Artelo Biosciences платеше дивиденда всяка година през последните 0 години.

За идните 12 месеца се очакват дивиденти в размер на 0 USD. Това съответства на дивидентна доходност от 0 %.

Artelo Biosciences се отнася за сектор 'Здраве'.

За да получите последното дивидентно плащане от Artelo Biosciences на 26.09.2024 г. в размер на 0 USD, трябваше да притежавате акцията в портфейла си преди Ex-деня на 26.09.2024 г..

Последното дивидентно плащане беше извършено на 26.09.2024 г..

През година 2023 Artelo Biosciences изплати 0 USD под формата на дивиденти.

Дивидентите от Artelo Biosciences се изплащат в USD.